In February 2022, the FDA granted accelerated approval to pacritinib for intermediate or high-risk primary or secondary myelofibrosis with severe thrombocytopenia.
March 1st 2022, 3:41am
Patients with myelofibrosis with severe thrombocytopenia and a platelet count below 50 × 109/L may derive benefit from treatment with pacritinib following its accelerated approval by the FDA.
March 4th 2022
March 2nd 2022